MEI Pharma, Inc. (MEIP)
Market Cap | 49.97M |
Revenue (ttm) | 58.77M |
Net Income (ttm) | -37.87M |
Shares Out | 6.66M |
EPS (ttm) | -5.52 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 21,700 |
Open | 7.55 |
Previous Close | 7.55 |
Day's Range | 7.28 - 7.55 |
52-Week Range | 4.00 - 13.60 |
Beta | 1.03 |
Analysts | Buy |
Price Target | 33.00 (+340.0%) |
Earnings Date | May 11, 2023 |
About MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and ... [Read more]
Financial Performance
In 2022, MEI Pharma's revenue was $40.70 million, an increase of 16.96% compared to the previous year's $34.80 million. Losses were -$54.45 million, 31.8% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for MEIP stock is "Buy." The 12-month stock price forecast is $33.0, which is an increase of 340.00% from the latest price.
News

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D.
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection ...

MEI Pharma Board of Directors Rejects Unsolicited Proposal
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that its Board of Directors (the “Board”) reviewed and rejected the unsolicited and non-binding proposal rec...

MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisor...

MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced an update to the Phase 1 study evalu...

MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 3...

MEI Pharma Announces 1-for-20 Reverse Stock Split
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved...

SHAREHOLDER ALERT: Weiss Law Investigates Infinity Pharmaceuticals, Inc.
NEW YORK , Feb. 28, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity Pharmaceuticals, Inc. ("Infini...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.
NEW YORK , Feb. 23, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and its board of directors concerning the...

MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of MEI Pharma, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of MEI Pharma, Inc. (NASDAQ: MEIP) and Infinity Pharmaceuticals, Inc. is fair to MEI share...

MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
SAN DIEGO, CA. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmac...

MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended Decembe...

MEI Pharma Announces Adjournment of Annual Meeting of Stockholders
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been ...

MEI Pharma Initiates Strategic Realignment
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realig...

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Jap...

Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan
TOKYO & SAN DIEGO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology...

MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September...

MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd.

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options fo...

MEI Pharma Announces Changes to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Christine A. White, M.D., has decid...

MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30...

MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright...

MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 f...

MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 415...

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry...

MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 415...